{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:22:17Z","timestamp":1794666137427,"version":"4.9.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>This scoping review evaluates the economic impact of therapeutic drug monitoring (TDM) and model-informed precision dosing (MIPD), incorporating clinical pharmacokinetics principles in pediatric populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This study followed the PRISMA-ScR guidelines. From 1057 articles identified, 8 met inclusion criteria (5 retrospective studies and 3 Markov-based simulations) focusing on the following drugs: PEG-asparaginase, valproic acid, carbamazepine, phenytoin, phenobarbital, vancomycin, adalimumab, tobramycin, cyclosporine, and perampanel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Most studies reported cost savings or improved cost-effectiveness with TDM-MIPD strategies. However, analyses were limited to direct medical costs, with little consideration of indirect or societal costs. Also, methodological heterogeneity limited direct comparisons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The lack of standardized methodologies and economic endpoints, along with potential underreporting of negative findings, restricts the generalizability of conclusions. Nevertheless, current evidence supports TDM-MIPD as a potentially cost-effective approach in pediatric pharmacotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001424","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T05:01:11Z","timestamp":1766034071000},"page":"540-546","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Economic Evaluation of Therapeutic Drug Monitoring and Precision Dosing in Pediatrics: A Short Communication"],"prefix":"10.1097","volume":"48","author":[{"given":"V\u00edctor E.","family":"Lechuga-Noa","sequence":"first","affiliation":[{"name":"Cardiovascular Pharmacy, Instituto Nacional Cardiovascular\u2013INCOR-EsSalud, Lima, Per\u00fa;"},{"name":"Grupo Peruano de Investigaci\u00f3n en Medicamentos, Pol\u00edticas y Servicios farmac\u00e9uticos, Universidad Cient\u00edfica del Sur, Lima, Per\u00fa; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo Federico","family":"Taboada","sequence":"additional","affiliation":[{"name":"Pharmacokinetics and Clinical Pharmacology Research Unit, Pharmacy Area, Hospital de Pediatria J.P Garrahan, Buenos Aires, Argentina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"C\u00e1ceres Guido","sequence":"additional","affiliation":[{"name":"Pharmacokinetics and Clinical Pharmacology Research Unit, Pharmacy Area, Hospital de Pediatria J.P Garrahan, Buenos Aires, Argentina."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"R1-20261114","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3390\/antibiotics11091142","article-title":"Use of antibiotics in preterm newborns","volume":"11","author":"Simeoli","year":"2022","journal-title":"Antibiotics (Basel)"},{"issue":"suppl 1","key":"R2-20261114","first-page":"S81","article-title":"A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012","volume":"18","author":"Tolou-Ghamari","year":"2013","journal-title":"J Res Med Sci"},{"issue":"suppl 1","key":"R3-20261114","first-page":"S60","article-title":"Model-informed drug development in pediatric dose selection","volume":"61","author":"Bi","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"R4-20261114","doi-asserted-by":"crossref","first-page":"624639","DOI":"10.3389\/fped.2021.624639","article-title":"Model-informed precision dosing of antibiotics in pediatric patients: a narrative review","volume":"9","author":"Abdulla","year":"2021","journal-title":"Front Pediatr"},{"key":"R5-20261114","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/cpt.2202","article-title":"From therapeutic drug monitoring to model-informed precision dosing for antibiotics","volume":"109","author":"Wicha","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"R6-20261114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00007691-200202000-00001","article-title":"Review: therapeutic drug monitoring in pediatrics","volume":"24","author":"Soldin","year":"2002","journal-title":"Ther Drug Monit"},{"key":"R7-20261114","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.vhri.2021.11.001","article-title":"Est\u00e1ndares consolidados de reporte de evaluaciones econ\u00f3micas sanitarias: adaptaci\u00f3n al espa\u00f1ol de la lista de comprobaci\u00f3n CHEERS 2022","volume":"27","author":"Augustovski","year":"2022","journal-title":"Value Health Reg Issues"},{"key":"R8-20261114","doi-asserted-by":"crossref","first-page":"e26651","DOI":"10.1002\/pbc.26651","article-title":"A cost analysis of individualized asparaginase treatment in pediatric acute lymphoblastic leukemia","volume":"64","author":"Kloos","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"R9-20261114","doi-asserted-by":"crossref","first-page":"e29051","DOI":"10.1002\/pbc.29051","article-title":"Premedication prior to PEG-asparaginase is cost-effective in pediatric patients with acute lymphoblastic leukemia","volume":"68","author":"McCormick","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"R10-20261114","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eplepsyres.2012.09.012","article-title":"Cost-effectiveness analysis for the use of serum antiepileptic drug level monitoring in children diagnosed with structural-metabolic epilepsy","volume":"104","author":"Salih","year":"2013","journal-title":"Epilepsy Res"},{"key":"R11-20261114","first-page":"159","article-title":"Inappropriate vancomycin therapeutic drug monitoring in hospitalized pediatric patients increases pediatric trauma and hospital costs","volume":"17","author":"Suryadevara","year":"2012","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R12-20261114","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1111\/jgh.15373","article-title":"Proactive therapeutic drug monitoring of adalimumab for pediatric Crohn's disease patients: a cost-effectiveness analysis","volume":"36","author":"Yao","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"R13-20261114","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/ppul.22745","article-title":"Clinical pharmacist impact on care, length of stay, and cost in pediatric cystic fibrosis (CF) patients","volume":"48","author":"Cies","year":"2013","journal-title":"Pediatr Pulmonol"},{"key":"R14-20261114","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/FTD.0000000000000886","article-title":"Impact of a bayesian individualization of cyclosporine dosage regimen for children undergoing allogeneic hematopoietic cell transplantation: a cost-effectiveness analysis","volume":"43","author":"Beyron","year":"2021","journal-title":"Ther Drug Monit"},{"key":"R15-20261114","doi-asserted-by":"crossref","first-page":"1549069","DOI":"10.3389\/fphar.2025.1549069","article-title":"Cost-effectiveness of therapeutic drug monitoring of perampanel for pediatrics with epilepsy: real-world data","volume":"16","author":"Hu","year":"2025","journal-title":"Front Pharmacol"},{"key":"R16-20261114","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/ibd\/izaa073","article-title":"A systematic review on cost-effectiveness analyses of therapeutic drug monitoring for patients with inflammatory bowel disease: from immunosuppressive to Anti-TNF therapy","volume":"27","author":"Yao","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"R17-20261114","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.3390\/pharmaceutics14051009","article-title":"Cost-effectiveness of therapeutic drug monitoring of Anti-TNF therapy in inflammatory bowel disease: a systematic review","volume":"14","author":"Marquez-Megias","year":"2022","journal-title":"Pharmaceutics"},{"key":"R18-20261114","doi-asserted-by":"crossref","first-page":"152302","DOI":"10.1016\/j.semarthrit.2023.152302","article-title":"Efficacy, safety, and cost-effectiveness of therapeutic drug monitoring (TDM) for TNF inhibitor therapy in rheumatic disease: a systematic review and meta-analysis","volume":"63","author":"Dong","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"R19-20261114","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/FTD.0000000000001067","article-title":"Optimization of antimicrobial stewardship programs using therapeutic drug monitoring and pharmacokinetics-pharmacodynamics protocols: a cost-benefit review","volume":"45","author":"Telles","year":"2023","journal-title":"Ther Drug Monit"},{"key":"R20-20261114","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1111\/bcp.16164","article-title":"Economic evaluations of therapeutic drug monitoring interventions in acute hospital-based settings: a systematic review","volume":"90","author":"Carland","year":"2024","journal-title":"Br J Clin Pharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:00:34Z","timestamp":1794664834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001424","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"2025-07-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}